Brazilian embauba (Cecropia pachystachya) extract reduces renal lesions in 5/6 nephrectomized rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 4, 2014, Pages 430-439

  Do C Maquiaveli, Claudia ^a   Da Silva, Edson R ^a   Francescato, Heloísa D C ^a   Costa, Roberto S ^a   Silva, Cleonice G A ^a   Casarini, Dulce E ^b   Ronchi, Fernanda A ^b   Coimbra, Terezila M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

angiotensin II; Cecropia pachystachya; inflammation; renal failure

Indexed keywords

ALBUMIN; ANGIOTENSIN II; CECROPIA PACHYSTACHYA EXTRACT; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; PROTECTIVE AGENT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN; CCL2 PROTEIN, RAT;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD PRESSURE; BODY WEIGHT; BRUSH BORDER; CECROPIA PACHYSTACHYA; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HYPERTENSION; INFLAMMATORY CELL; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; LIQUID CHROMATOGRAPHY; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE OSMOLALITY; URTICACEAE; ANIMAL; BRAZIL; CECROPIA; CHEMISTRY; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TEST; OSMOLARITY; PATHOLOGY; PATHOPHYSIOLOGY; SURGERY; SYSTOLE; URINE; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; BRAZIL; CECROPIA PLANT; CHEMOKINE CCL2; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NEPHRECTOMY; OSMOLAR CONCENTRATION; PLANT EXTRACTS; RATS, WISTAR; SYSTOLE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84918508594     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313501219     Document Type: Article

References (36)

1. Monteiro de Freitas AS, Coimbra TM, Costa RS, et al. Urinary transforming growth factor-beta (TGF-beta) excretion and renal production of TGF-beta in rats with subtotal renal ablation: Effect of enalapril and nifedipine. Nephron. 1998 ; 78: 302-309
2. Yang N, Wu LL, Nikolic-Paterson DJ, et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol DialTransplant. 1998 ; 13: 1967-1974
3. Gretz N, Waldherr R, Strauch M Experimental and genetic rat models of chronic renal failure. Gretz N Strauch M, ed. New York: Basel Bublishing ; 1993: 1-29.
4. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000 ; 57: 1803-1817
5. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol. 1989 ; 135: 719-733
6. Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant. 2004 ; 19: 277-281
7. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998 ; 53: 1608-1615
8. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000 ; 15: 290-301
9. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994 ; 93: 2431-2437
10. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 ; 331: 1286-1292
11. Kim S, Izumi Y, Yano M, et al. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation. 1998 ; 97: 1731-1737
12. Esteban V, Lorenzo O, Rupérez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004 ; 15: 1514-1529
13. Costa JC, Costa RS, Silva CG, et al. Enalapril reduces the expression of nuclear factor-kappaB and c-Jun N-terminal kinase in the renal cortices of five-sixths-nephrectomized rats. Am J Nephrol. 2006 ; 26: 281-286
14. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 ; 329: 1456-1462
15. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 ; 334: 939-945
16. Luenga-Caicedo PE, Braga FC, Brandão GC, et al. Seasonal and intraspecific varation of flavonoids and proanthocyanidins in Cecropia glaziovi sneth. Leaves from native and cultivated specimens. Z Naturforsch C. 2007 ; 62: 701-709
17. Aragão DM, Guarize L, Lanini J, et al. Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats. J Ethnopharmacol. 2010 ; 128: 629-363
18. Gallo MB, Vieira PC, Fernandes JB, et al. Compounds from Vitex polygama active against kidney diseases. J Ethnopharmacol. 2008 ; 115: 320-322
19. Aragão DM, Lima IVA, Silva JM, et al. Anti-inflammatory, antinociceptive and cytotoxic effects of the methanol extract of Cecropia pachystachya Trécul. J Phytother. 2013 ; 27: 926-930
20. Actis-Goretta L, Ottaviani JI, Fraga CG. Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. J Agric Food Chem. 2006 ; 54: 229-234
21. Ottaviani JI, Actis-Goretta L, Villordo JJ, et al. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition. Biochimie. 2006 ; 88: 359-365
22. Lacaille-Dubois Franck U, Wagner H. Search for potential angiotensin converting enzyme (ACE)-inhibitors from plants. Phytomedicine. 2001 ; 8: 47-52
23. Chanutin A, Ferris EB. Experimental renal insufficiency produced by partial nephrectomia. Arch Int Med. 1932 ; 49: 767-787
24. Coimbra TM, Furtado MR, Lachat JJ, et al. Effects of administration of cationic and native homologous albumin on the kidney. Nephron. 1983 ; 33: 208-215
25. Fuhr J, Kaczmarczyk J, Kruttgen CD. A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics. Klin Wochenschr. 1955 ; 33: 729-730
26. Friedland J, Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol. 1976 ; 66: 416-24
27. Oliveira EM, Santos RA, Krieger JE. Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats. Braz J Med Biol Res. 2000 ; 33: 755-764
28. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996 ; 49: 666-678
29. Coimbra TM, Janssen U, Gröne HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000 ; 57: 167-182
30. Navar LG, Harrison-Bernard LM. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res. 2000 ; 23: 291-301
31. Navar LG, Mitchell KD, Harrison-Bernard LM, et al. Intrarenal angiotensin II levels in normal and hypertensive states. J Renin Angiotensin Aldosterone Syst. 2001 ; 2: S176 - S184
32. Eardley KS, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 2005 ; 68: 437-455
33. Noh JW, Wiggins R, Phan SH. Urine transforming growth factor-beta activity is related to the degree of scarring in crescentic nephritis in the rabbit. Nephron. 1993 ; 63: 73-78
34. Dominguez GCS, Costa RS, Dantas M, et al. Transforming growth factor beta activity in urine of patients with glomerulonephritis is related to their renal functional and structural changes. Nephrology. 1998 ; 4: 31-35
35. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006 ; 69: 1189-1197
36. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997 ; 51: 2-15